Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. (Q37579644)

From Wikidata

Jump to navigation Jump to search

scientific article published on August 2009

Language	Label	Description	Also known as
English	Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.	scientific article published on August 2009

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680292%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

Europe PubMed Central

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680292%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

0 references

mutational analysis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680292%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680292%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Ming-Sound Tsao

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680292%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

T John

1

1 reference

Europe PubMed Central

21 August 2017

M-S Tsao

3

1 reference

Europe PubMed Central

21 August 2017

language of work or name

0 references

publication date

1 August 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680292%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680292%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

28 Suppl 1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680292%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

S14-23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680292%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

https://scigraph.springernature.com/pub.10.1038/onc.2009.197

0 references

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

K-ras mutations in non-small-cell lung carcinoma: a review

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Predictors of the response to gefitinib in refractory non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

EGFR and erbB2 mutation status in Japanese lung cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Detection of PCR products using self-probing amplicons and fluorescence

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

21 January 2018

Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Detection of DNA sequences in nuclei in suspension by in situ hybridization and dual beam flow cytometry

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone r

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

31 March 2020

Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.197

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37579644&oldid=1523820787"